Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YN001 Pharmacokinetics in Healthy Participants
NCT07190885Phase 1Suspended
- Sponsor
- Beijing Inno Medicine Co., Ltd.
- Start
- Nov 2025
- Primary completion
- Sep 2026
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YN001, sponsored by Beijing Inno Medicine Co., Ltd. Primary endpoints: Maximum plasma concentration, Time to reach maximum plasma concentration and 6 more. Started Nov 2025; status: suspended.
02
Drugs
YN001
Beyond the preview
Go deeper on NCT07190885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07190885.